Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | SignaBlok Awarded NIH Grant to Develop New Nanotechnology for Diagnostic Imaging of AtherosclerosisSignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Institutes of Health (NIH) to develop multifunctional nanoformulations for diagnostic imaging of atherosclerosis.
By: SignaBlok, Inc. SignaBlok’s proprietary nanosystem for delivery of drugs and imaging agents targets macrophages, inflammatory cells that are critically involved in plaque formation and have a high discriminatory power to identify the vulnerable plaque. The goal of this grant is to validate a novel approach to macrophage-targeted delivery of MRI contrast agents in a clinically relevant animal model of atherosclerosis. “We are extremely pleased by the award of this SBIR grant from the NHLBI/NIH,” said Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. “The proposed research will result in the development of novel imaging techniques that would fill an important unmet medical need in the diagnosis and treatment of atherosclerosis. This would offer better way to identify high-risk individuals, provide earlier diagnosis before symptoms occur and monitor treatment effects.” “Macrophages are important imaging targets for diagnosis and image-guided therapy of not only atherosclerosis but also cancer. Thus, this grant gives us an opportunity to develop targeted nanosystem for in vivo macrophage imaging with a wide range of clinical applications,” About atherosclerosis: About SignaBlok SignaBlok is developing a new class of therapies – SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy. Additional information about SignaBlok is available at signablok.com. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|